Structure Therapeutics Inc.
Financials
Valuation Metrics
Structure Therapeutics Inc.'s Market Cap is $1.45B. At end of 2025 it was $4.12B. Ranked #2148 of 3,118 in US market (top 69%), #833 of 1,474 on NASDAQ (top 57%), #155 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 58%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.45B | US#2,148/3,118 Sec#155/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-215M | US—/3,118 Sec—/265 |
| Total Assets | $1.43B | US#2,277/3,118 Sec#71/265 |
| Net Assets | $1.35B | US#1,545/3,118 Sec#47/265 |
| Employees | 233 | US#2,453/3,118 Sec#122/265 |
| Value | ||
| P/B | 1.07x | US#553/3,118 Sec#27/265 |
| FCF Yield | -15.44% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -15.88% | US#2,429/3,118 Sec#92/265 |
| ROA | -15.09% | US#2,736/3,118 Sec#118/265 |
| Financial Health | ||
| Debt Ratio | 5.24% | US#39/3,118 Sec#14/265 |
| Total Debt | $6M | US#2,865/3,118 Sec#210/265 |
| FCF | $-224M | US#2,798/3,118 Sec#217/265 |
| Cash | $273M | US#1,480/3,118 Sec#88/265 |
| Current Ratio | 20.75x | US#114/3,118 Sec#24/265 |
| Performance | ||
| 1Y Return | -38.61% | US#2,631/3,118 Sec#211/265 |
| 1M Return | -26.08% | US#2,991/3,118 Sec#251/265 |
| From 52W High | -78.45% | US#3,028/3,118 Sec#248/265 |
| 1Y MDD | -78.19% | US#3,016/3,118 Sec#241/265 |
| Trading | ||
| Volume | 695,978 shares | US#1,879/3,118 Sec#184/265 |
| Trading Value | $15M | US#2,119/3,118 Sec#159/265 |
| Per Share | ||
| EPS | $-3.03 | US—/3,118 Sec—/265 |
| BPS | $19.06 | US#1,287/3,118 Sec#31/265 |
Company Info
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.